Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
News|Articles|January 18, 2022
Bristol Myers Squibb and Prellis Biologics Partner to Build Human Antibody Libraries
Author(s)Pharmaceutical Technology Editors
In their collaboration, Bristol Myers Squibb and Prellis Biologics aim to generate human antibody libraries for select targets to enable drug discovery.
Advertisement
Prellis Biologics, a US-based biotechnology company, announced on Jan. 13, 2022 that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb, which will utilize Prellis’ externalized human immune system (EXIS) to create high-affinity human antibodies targeting human proteins.
Under the agreement, Prellis and Bristol Myers Squibb will generate human antibody libraries for select targets. Bristol Myers Squibb will pay Prellis an undisclosed up-front payment and funding for research activities as well as development, sales milestones, and royalties for licensed antibodies.
Prellis’ EXIS platform is based on human lymph node organoids, which can break tolerance mechanisms in vitro allowing for the creation of high affinity human antibodies.
"…[T]he EXIS platform provides high affinity antibodies, derived from lymph node organoids printed with Prellis’ foundational technology, using human PBMCs [peripheral blood mononuclear cells]," said Melanie P. Matheu, founder and CEO of Prellis, in a company press release. "We are looking forward to working with Bristol Myers Squibb to demonstrate advantages of in-vitro human antibody discovery with the EXIS platform."
"The EXIS platform effectively breaks tolerance, enabling direct discovery of human antibodies to challenging human antigens in less than two week," said Kevin Chapman, chief scientific officer of Prellis, in the press release.
Source: Prellis Biologics
Advertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
Advertisement
Advertisement